https://doi.org/10.4081/ejtm.2025.14272
Analysis of the effects of dapagliflozin on cardiac myocyte injury markers and left ventricular diastolic function in heart failure patients with preserved ejection fraction after percutaneous coronary intervention
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 4 December 2025
The objective of this study was to analyze the effects of Dapagliflozin on cardiac myocyte injury markers and left ventricular diastolic function in patients with Heart Failure with Preserved Ejection Fraction (HF-PEF) after Percutaneous Coronary Intervention (PCI). The study included 120 HF-PEF patients post-PCI treated at our hospital between May 2021 and May 2024. Patients were divided into two groups: conventional therapy (n=49) and Dapagliflozin plus conventional therapy (n=71). Serum Cardiac Troponin I (cTnI) and Serum Amyloid A (SAA) were measured. Left ventricular function was assessed by Ejection Fraction (EF) and the E/e’ ratio. The incidence of Major Adverse Cardiovascular Events (MACE) was also recorded. After treatment, the Dapagliflozin group showed significantly lower cTnI and SAA levels compared to the conventional group (p<0.05). EF was higher and E/e’ ratio was lower in the Dapagliflozin group (p<0.05). The incidence of MACE was reduced to 1.41% versus 12.24% in the conventional group (p<0.05). In conclusion, Dapagliflozin effectively reduces cardiac myocyte injury markers, improves left ventricular diastolic function, and lowers the incidence of MACE in HF-PEF patients after PCI, demonstrating significant translational benefits for cardiac muscle function.
Downloads
[1] O’Donovan AN, Herisson FM, Fouhy F, et al. Gut microbiome of a porcine model of metabolic syndrome and HF-pEF. Am J Physiology-Heart Circulat Physiol 2020;318:H590-603. DOI: https://doi.org/10.1152/ajpheart.00512.2019
[2] Gao M, Bai W, Cheng S, QI X. Recent Evidence on Angiotensin Receptor-neprilsin Inhibitor in Heart Failure with Preserved Ejection Fraction. Chinese General Practice 2021;24:2967.
[3] Yang J, Lv T, Zhou J, et al. The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis. Front Cardiovasc Med 2023;10:1149351. DOI: https://doi.org/10.3389/fcvm.2023.1149351
[4] Mentz RJ, Brunton SA, Rangaswami J. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review. Cardiovasc Diabetol 2023;22:316. DOI: https://doi.org/10.1186/s12933-023-02023-y
[5] Li H, Qin X, Zhang L, et al. Effect of SGLT2 inhibitors on inflammatory markers and oxygen consumption in non-diabetic patients with STEMI undergoing primary PCI: A parallel design single blind controlled trial. Heart & Lung 2025;73:174-9. DOI: https://doi.org/10.1016/j.hrtlng.2025.05.010
[6] Li S, Wang L, Wang P, et al. Dapagliflozin improves cardiac function and reduces adverse events in myocardial infarction: a meta-analysis in diabetic and non-diabetic populations. Front Endocrinol 2025;16:1594861. DOI: https://doi.org/10.3389/fendo.2025.1594861
[7] Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2024. Cardiol Discovery 2025;5:1-38. DOI: https://doi.org/10.1097/CD9.0000000000000146
[8] Perticone M, Gigliotti S, Shehaj E, et al. Gut permeability and immune-mediated inflammation in heart failure. Biomedicines 2024;12:1217. DOI: https://doi.org/10.3390/biomedicines12061217
[9] Mohammed MA. Nurses knowledge regarding post cardiac arrest care in intensive care unit of omdurman military hospital on March to September 2017. Doctoral dissertation.
[10] Wang F, Li C, Zhang X. Sacubitril/valsartan improves the prognosis of acute myocardial infarction: a meta-analysis. Coron Artery Dis 2024;35:231-8. DOI: https://doi.org/10.1097/MCA.0000000000001332
[11] Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005;95:13-9. DOI: https://doi.org/10.1016/j.amjcard.2004.08.056
[12] Lin X, Fang L. Pharmaceutical Treatment for Heart Failure. Adv Exp Med Biol 2020;1177:269-95. DOI: https://doi.org/10.1007/978-981-15-2517-9_7
[13] Wang H, Liu C, Guo X, et al. Effects of modified Danggui Sini Decoction as adjuvant therapy for angina pectoris in coronary heart disease: a systematic review and meta-analysis based on randomised controlled trials. Front Pharmacol 2024;15:1375795. DOI: https://doi.org/10.3389/fphar.2024.1375795
[14] Zhao Z, Zheng N, Zhang T, et al. Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study. Cardiovasc Diabetol 2025;24:185. DOI: https://doi.org/10.1186/s12933-025-02678-9
[15] Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59. DOI: https://doi.org/10.1007/s40265-014-0337-y
[16] Liu C, Guo X, Wang H, Zhou Y. Combination of Qi benefiting and blood circulation promoting herbs with Dapagliflozin in the treatment of type 2 diabetes mellitus combined with heart failure: a systematic evaluation and meta-analysis based on a randomized controlled trial. Complement Med Res 2024;31:551-66. DOI: https://doi.org/10.1159/000541234
CRediT authorship contribution
All authors contributed equally to the paper.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.